Aldosterone Synthase & Hypertension
Aldosterone Synthase & Hypertension
批准号:
8837685
负责人:
ASHOK KUMAR
金额:
$62.29万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2018-05-31
关键词:
Adipose tissueAdrenal CortexAdrenal GlandsAldosteroneAldosterone SynthaseAllelesAnabolismAngiotensin IIAnimalsBase SequenceBindingBinding SitesBiologicalBlood PressureBrainCardiovascular DiseasesCardiovascular systemCaucasiansCellsCholesterolCodeDietElderlyEnzymesEpidemiologic StudiesEquilibriumExonsFatty acid glycerol estersFemaleGenesGenetic PolymorphismGenomic DNAHaplotypesHealthHeart failureHumanHypertensionHypertrophyIn VitroIntronsKidneyKidney FailureKnock-in MouseMessenger RNAMolecularMusMyocardialMyocardial InfarctionNamesOligonucleotidesPlasmaPlayProductionProteinsReagentRecombinantsRegulationRenin-Angiotensin-Aldosterone SystemReporterReporter GenesRisk FactorsRoleSF1Sodium ChlorideStrokeTimeTissuesTranscriptional RegulationTransfectionTransgenic AnimalsTransgenic MiceTransgenic OrganismsUntranslated RegionsVariantVascular Diseasesage relatedaldosterone hypertensionblood pressure reductionblood pressure regulationhuman subjectin vivomalenormotensivenovel therapeuticspromoterresearch studytranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Hypertension is a serious risk factor for myocardial infarction, heart failure, vascular disease, stroke, and renal failure. The renin-angiotensin-aldosterone system (RAAS) plays an important role in the regulation of blood pressure. Inappropriate increase of aldosterone causes age-related increase in blood pressure and other cardiovascular problems. Aldosterone is synthesized in the ZG of the adrenal cortex and aldosterone synthase is the rate limiting enzyme in its biosynthesis. Aldosterone synthase is coded by Cyp11B2 gene and the human gene has a T/C polymorphism located at -344 in its promoter. Epidemiological studies have suggested that variant -344T of Cyp11B2 gene is associated with hypertension and myocardial hypertrophy. Human Cyp11B2 gene has three SNPs in 1 Kb of its promoter that are in almost complete linkage dis-equilibrium. These SNPs are rs1799998 (T/C at -344), rs10087214 (C/T at -470), rs28659182 (C/A at -663). Thus variant -344T almost always occurs with variants -470C, -663A (named haplotype-I, and variant -344C almost always occurs with variants, - 470T, -663T (named haplotype-II). We have generated transgenic mice by knocking in hCyp11B2 gene containing either haplotype-I or haplotype-II at the HPRT locus. Transgenic mice containing haplotype-I have increased hCyp11B2 mRNA level in the adrenals and kidneys as compared to transgenic animals containing haplotype-II. In addition, male transgenic animals containing haplotype-I have increased blood pressure as compared to transgenic animals containing haplotype-II of hCyp11B2 gene. High salt (4% NaCl diet) and angiotensin-II administration increases blood pressure in transgenic mice containing haplotype-I of hCyp11B2 gene as compared to haplotype-II. Therefore, our hypothesis is that transcription factors bind strongly to the nucleotide sequence of hCyp11B2 gene containing haplotype-I as compared to haplotype-II, and increase its expression. This increases tissue or plasma aldosterone level in human subjects containing haplotype-I. The long term consequence of altered regulation of aldosterone production leads to an increase in blood pressure and cardiovascular complications in human subjects containing -344T allele as compared to -344C allele. These transgenic mice will be used to understand the role of these haplotypes on blood pressure regulation in male and female animals. Transgenic mice may also be used to develop new therapeutic reagents to reduce blood pressure and cardiovascular complications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TWEAK/Fn14/UPR Signaling in Skeletal Muscle Wasting
-
批准号:10660397
-
项目类别:
-
资助金额:$55.16万
-
财政年份:2023
-
负责人:ASHOK KUMAR
-
依托单位:
TAK1 signaling in skeletal muscle
-
批准号:10201515
-
项目类别:
-
资助金额:$42.97万
-
财政年份:2019
-
负责人:ASHOK KUMAR
-
依托单位:
TAK1 signaling in skeletal muscle
-
批准号:10005646
-
项目类别:
-
资助金额:$44.3万
-
财政年份:2019
-
负责人:ASHOK KUMAR
-
依托单位:
Non-Coding Variants of Angiotensinogen Gene and Hypertension
-
批准号:9197334
-
项目类别:
-
资助金额:$61.5万
-
财政年份:2016
-
负责人:ASHOK KUMAR
-
依托单位:
Non-Coding Variants of Angiotensinogen Gene and Hypertension
-
批准号:9325162
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2016
-
负责人:ASHOK KUMAR
-
依托单位:
MYD88 Signaling in Mammalian Myoblast Fusion
-
批准号:9144184
-
项目类别:
-
资助金额:$33.74万
-
财政年份:2015
-
负责人:ASHOK KUMAR
-
依托单位:
MYD88 Signaling in Mammalian Myoblast Fusion
-
批准号:9336240
-
项目类别:
-
资助金额:$33.74万
-
财政年份:2015
-
负责人:ASHOK KUMAR
-
依托单位:
Aldosterone Synthase & Hypertension
-
批准号:9052214
-
项目类别:
-
资助金额:$22.24万
-
财政年份:2014
-
负责人:ASHOK KUMAR
-
依托单位:
Aldosterone Synthase and Hypertension
-
批准号:8673375
-
项目类别:
-
资助金额:$63.24万
-
财政年份:2014
-
负责人:ASHOK KUMAR
-
依托单位:
TAK1/TRAF6 Signaling in Skeletal Muscle
-
批准号:8502172
-
项目类别:
-
资助金额:$31.99万
-
财政年份:2011
-
负责人:ASHOK KUMAR
-
依托单位:
Genetics of Hypertension
-
批准号:8302314
-
项目类别:
-
资助金额:$37.45万
-
财政年份:2011
-
负责人:ASHOK KUMAR
-
依托单位:
TAK1/TRAF6 Signaling in Skeletal Muscle
-
批准号:8286234
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2011
-
负责人:ASHOK KUMAR
-
依托单位:
Genetics of Hypertension
-
批准号:8392241
-
项目类别:
-
资助金额:$35.65万
-
财政年份:2011
-
负责人:ASHOK KUMAR
-
依托单位:
TAK1/TRAF6 Signaling in Skeletal Muscle
-
批准号:8690762
-
项目类别:
-
资助金额:$33.0万
-
财政年份:2011
-
负责人:ASHOK KUMAR
-
依托单位:
Genetics of Hypertension
-
批准号:8188803
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2011
-
负责人:ASHOK KUMAR
-
依托单位:
TAK1/TRAF6 Signaling in Skeletal Muscle
-
批准号:8106684
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2011
-
负责人:ASHOK KUMAR
-
依托单位:
Genetics of Hypertension
-
批准号:8585083
-
项目类别:
-
资助金额:$36.7万
-
财政年份:2011
-
负责人:ASHOK KUMAR
-
依托单位:
Transcriptional Regulation of Angiotensinogen Gene
-
批准号:8476249
-
项目类别:
-
资助金额:$35.3万
-
财政年份:2009
-
负责人:ASHOK KUMAR
-
依托单位:
Transcriptional Regulation of Angiotensinogen Gene
-
批准号:8413074
-
项目类别:
-
资助金额:$23.56万
-
财政年份:2009
-
负责人:ASHOK KUMAR
-
依托单位:
Transcriptional Regulation of Angiotensinogen Gene
-
批准号:7905982
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2009
-
负责人:ASHOK KUMAR
-
依托单位:
海外基金